HC Wainwright Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU)

HC Wainwright reiterated their buy rating on shares of AC Immune (NASDAQ:ACIU) in a report published on Wednesday, MarketBeat Ratings reports. HC Wainwright currently has a $16.00 price target on the stock.

Separately, BTIG Research began coverage on shares of AC Immune in a research note on Friday, May 31st. They set a buy rating and a $8.00 price objective on the stock.

AC Immune Stock Performance

Shares of NASDAQ:ACIU opened at $3.69 on Wednesday. The firm’s 50 day moving average is $3.43 and its two-hundred day moving average is $3.39. AC Immune has a 52 week low of $2.20 and a 52 week high of $5.14. The firm has a market capitalization of $364.94 million, a P/E ratio of -5.35 and a beta of 1.24.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million. Analysts predict that AC Immune will post -0.89 EPS for the current year.

Institutional Trading of AC Immune

Large investors have recently added to or reduced their stakes in the business. BVF Inc. IL boosted its stake in AC Immune by 96.2% in the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock worth $72,856,000 after purchasing an additional 7,142,857 shares during the period. Avidity Partners Management LP boosted its stake in AC Immune by 50.5% in the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company’s stock worth $22,345,000 after purchasing an additional 1,499,280 shares during the period. Assenagon Asset Management S.A. boosted its stake in AC Immune by 294.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after purchasing an additional 328,312 shares during the period. Platinum Investment Management Ltd. boosted its stake in AC Immune by 14.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock worth $7,578,000 after purchasing an additional 193,123 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after purchasing an additional 136,300 shares during the period. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.